Prevalence and spectrum of iron deficiency in heart failure patients in south Rajasthan  by Sharma, Sohan Kumar et al.
Original Article
Prevalence and spectrum of iron deficiency in heart
failure patients in south Rajasthan
Sohan Kumar Sharma a, Shalabh Kumar Agarwal b,*, Kapil Bhargava c,
Mukesh Sharma d, Karan Chopra b, Gopinath Arumugamb
aAssistant Professor, Department of Cardiology, RNT Medical College, Udaipur, Rajasthan 313001, India
b Senior Resident, Department of Cardiology, RNT Medical College, Udaipur, Rajasthan 313001, India
cProfessor and Head, Department of Cardiology, RNT Medical College, Udaipur, Rajasthan 313001, India
dProfessor, Department of Cardiology, RNT Medical College, Udaipur, Rajasthan 313001, India
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 9 3 – 4 9 7
a r t i c l e i n f o
Article history:
Received 26 August 2015
Accepted 28 October 2015
Available online 11 January 2016
Keywords:
Heart failure
Iron deﬁciency
Anemia
a b s t r a c t
Objective: To estimate the prevalence and pattern of iron deﬁciency (ID) in heart failure (HF)
patients with or without anemia.
Methods: This is a single-center observational study, conducted at a tertiary care hospital of
south Rajasthan. Patients admitted to hospital with clinical diagnosis of HF based on
validated clinical criteria were included in the study. ID was diagnosed based on complete
Iron proﬁle, including serum iron, serum ferritin, total iron binding capacity, and transferrin
saturation (TSAT). Anemia was deﬁned as hemoglobin (Hb) <13 g/dl for males and <12 g/dl
for females, based on World Health Organization deﬁnition. Absolute ID was taken as serum
ferritin < 100 mg/L and functional ID was deﬁned as normal serum ferritin (100–300 mg/L)
with low TSAT (<20%).
Results: A total of 150 patients of HF (68% males and 32% females) were studied. Most of the
patients were of high-functional NYHA class (mean NYHA 2.89  0.95). ID was present in 76%
patients with 48.7% patients having absolute and 27.3% patients having functional ID.
Females were having signiﬁcantly higher prevalence of ID than males (91.6% vs 68.6%;
p = 0.002). Nearly one-fourth of the patients were having ID but without anemia, signifying
importance of workup of ID other than Hb.
Conclusion: Our study highlights the yet underestimated and neglected burden of ID in HF
patients in India. This study suggests further large-scale studies to better characterize this
easily treatable condition and considering routine testing in future Indian guidelines.
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Total patients 150
Males 102 (68%)
Females 48 (32%)
Mean age (years) 63.3  14.4
Males 62.2  14.3
Females 65.4  14.4
Age groups
<50 Years 40 (26.7%)
51–70 Years 65 (43.3%)
>70 Years 45 (30.0%)
NYHA class – Mean 2.89  0.95
NYHA-I 16 (10.7%)
NYHA-II 27 (18.0%)
NYHA-III 64 (42.7%)
NYHA-IV 43 (28.7%)
Ejection fraction – Mean (%) 38  12
<30% 54 (36.0%)
31–44% 54 (36.0%)
45–50% 5 (3.4%)
>50% 37 (24.7%)
Diabetes 23 (15.3%)
Hypertension 65 (43.3%)
Ischemic Heart Disease 81 (54.0%)
Primary valvular heart disease 23 (15.3%)
Secondary mitral regurgitation 57 (38.0%)
Atrial ﬁbrillation 32 (21.3%)
Wide QRS 19 (12.7%)1. Introduction
Heart failure (HF) is a common problem with a prevalence of 1–
2% in general population and a major cause of mortality,
morbidity, and impaired quality of life (QoL).1,2 Anemia is a
frequent comorbidity in stable HF patients3 and it increases
morbidity in terms of frequent hospital admissions, impaired
exercise capacity, poor QoL, and increased mortality. Iron
deﬁciency (ID) with or without anemia has been commonly
associated with HF. Although ID is the commonest nutritional
deﬁciency worldwide, affecting more than one-third of the
population,4 its association with HF with or without anemia is
of growing interest.5–7 As iron supplementation improves
prognosis in patients with HF, ID is an attractive therapeutic
target – a hypothesis that has recently been tested in clinical
studies.8,9
In 2012, the European Society of Cardiology (ESC) Guidelines
for the diagnosis and treatment of acute and chronic HF
recognized ID as a comorbidity in HF for the ﬁrst time and
recommended diagnosis of ID based on iron parameters in all
patients suspected of having HF.10,11
Most of the studies of prevalence of ID associated with HF
are from the western world. Few studies evaluated this
association in Asian patients12,13 but currently there are no
data from India to permit an estimation of the prevalence of ID
associated with HF. This study is intended to assess the
prevalence of ID in HF and may help in formulating future
guidelines in India for routine ID assessment in HF patients.
2. Material and methods
This study is a single-center observational study, conducted at
a tertiary care hospital of south Rajasthan from January 2015 to
July 2015. The objective of the study was to estimate the
prevalence and spectrum of ID in HF patients.
Male or female patients above 18 years of age and clinically
diagnosed with HF, who gave consent for the study, were
included. Diagnosis of HF was established based on validated
clinical criteria from the ESC,10 the ESC guidelines for the
diagnosis of HF with preserved ejection fraction (HFPEF),14
and the Framingham criteria.15 Excluded patients were those
who had comorbid noncardiac conditions causing ID (e.g.
hemorrhoids, malignancy, etc.) or confounding assignment
of etiology for ﬂuid overload (e.g. end-stage renal failure), as
well as patients with speciﬁc etiologies (e.g. congenital heart
disease), who would be expected to follow a different natural
history compared with a 'typical' HF patient. All participants
underwent thorough history (including dietary history) and
clinical evaluation, blood sampling, and comprehensive
transthoracic echocardiography using standardized equip-
ment (Vivid 7 from General Electric Company). Patients
were characterized as having normal Ejection Fraction
(EF ≥ 50%) or mild (EF 45–50%), moderate (EF 31–44%), or
severe (EF ≤ 30%) LV systolic dysfunction. Apart from routine
hemogram, these patients were assessed for their iron status
by measuring complete iron proﬁle, including serum iron,
serum ferritin, total iron binding capacity, and transferrin
saturation (TSAT).Anemia was deﬁned as hemoglobin (Hb) < 13 g/dl for males
and <12 g/dl for females, based on World Health Organization
deﬁnition.16 Although generally accepted serum ferritin cut-
off level to diagnose absolute ID is 30 mg/L, in HF, both
intracellular iron accumulation and inﬂammation stimulate
the tissue expression of ferritin and increase its blood level. In
such cases, for the diagnosis of absolute ID, a higher serum
ferritin cut-off value is used (e.g. 100 mg/L).4 In our study,
absolute ID was taken as serum ferritin < 100 mg/L and
functional ID was deﬁned as normal serum ferritin (100–
300 mg/L) with low TSAT (<20%).6,8,17
2.1. Statistical analysis
Categorical variables are expressed in numbers and percen-
tages, whereas normally distributed data are presented as
mean  standard deviation. Chi-square test and Student's t-
test were used to calculate p-value as appropriate.
3. Results
During the period of study, 150 patients admitted to hospital
with clinical diagnosis of HF were studied, out of which 102
(68%) were males and 48 (32%) were females. Mean age of the
study subjects was 63.3  14.4 years, with mean NYHA class of
2.89  0.95 and mean EF of 38  12%. Baseline characteristics
of these patients are shown in Table 1.
Absolute ID (serum ferritin < 100 mg/L) was present in 73
(48.7%) patients. Absolute ID with anemia (Hb < 13 g% for male
and <12 g% for females) was present in 47 (31.3%) patients.
Table 2 – Status of iron deficiency (ID) of study population.
Males (n = 102) Females (n = 48) Total (n = 150)
Absolute ID 39 (38.2%) 34 (70.8%) 73 (48.7%)
With anemia 24 23 47 (31.3%)
Without anemia 15 11 26 (17.4%)
Functional ID 31 (30.3%) 10 (20.8%) 41 (27.3%)
With anemia 22 8 30 (20%)
Without anemia 9 2 11 (7.3%)
Absolute or functional ID 70 (68.6%) 44 (91.6%) 114 (76%)
With anemia 46 31 77 (51.3%)
Without anemia 24 13 37 (24.7%)
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was present in 41 (27.3%) patients and functional ID with anemia
was present in 30 (20%) patients.
Thus ID (either absolute or functional) was found in 114
(76%) patients and ID with anemia was present in 77 (51.3%)
patients (Table 2).
Females had a signiﬁcantly higher prevalence of ID cf.
males (91.6% vs 68.6%; p = 0.002).
Patients with ID with anemia were stratiﬁed as per their Hb
level. Majority (68.8%) of these patients were having mild
anemia (Hb:10–13 g/dl for males and 10–12 g/dl for females)
(Table 3).
Patients with ID were further categorized as per their NYHA
functional class and Left ventricular systolic function (as
assessed by ejection fraction) (Table 4).
Those with absolute ID had mean NYHA class of 2.94  0.87,
those with functional ID – 2.90  0.90, and without ID of 2.87
 0.97 ( p value NS).Table 3 – Characteristics of anemia in patients with ID
with anemia.
Hemoglobin (g/dl) Males Females Total
<13 for males and <12
for females
46 31 77
10–13 for males and 10–12
for females
36 17 53 (68.8%)
8–10 7 11 18 (23.4%)
<8 3 3 6 (7.8%)
Table 4 – Categorization of patients with ID as per their
functional class and LV function.
Males Females Total
NYHA class
I 9 2 11 (9.6%)
II 17 6 23 (20.3%)
III 29 25 54 (46.3%)
IV 15 11 26 (22.8%)
LV function
EF < 30% 21 13 34 (29.8%)
31–44% 31 16 47 (41.2%)
45–50% 1 2 3 (2.6%)
>50% 17 13 30 (26.4%)4. Discussion
The ﬁndings from our study highlight a remarkably high
prevalence of ID in HF patients in Indian population. ID is
prevalent in HF patients even without anemia, which is
already an established poor prognostic factor.
In recent years, there is increasing awareness worldwide of
the signiﬁcance of ID in patients of HF. In the USA, a
prospective study of community-dwelling adults with self-
reported HF revealed a prevalence rate of 61.3%.18 In Europe,
prevalence rates ranging from 37% to 50%.5,17 have been
reported. In our study, we found the prevalence of ID being
76%, which is signiﬁcantly higher than these studies. This also
highlights the burden of this condition in Indian HF patients. A
study by Yeo et al. done in multiethnic Asian population,
suggesting HF patients of Indian ethnicity having highest rates
of ID, also supports our ﬁndings.21
On gender-based analysis, we found that ID was signiﬁ-
cantly higher in women with HF as compared to men. With a
mean age of 65.4  14.4 years, the women in our study were
mostly post-menopausal, making blood loss of menstruation
(an otherwise common cause of ID in women) a very unlikely
cause of ID. This ﬁnding is in accordance with previous studies
that suggested female gender as an independent correlate of
ID in HF.5,12,17
In this study, 76% patients were having ID and 51.3% had ID
with anemia. A signiﬁcant number of patients (24.7%) were
having ID but no anemia. Thus, if Hb levels are taken into
consideration for workup of ID in HF patients, a signiﬁcant part
of the putative iceberg would have been missed. With 27.3%
prevalence, functional ID is also making a signiﬁcant part of
disease burden. This subset will remain unrevealed unless
care is taken to consider TSAT and serum ferritin in the
workup. A recent article by Yeo et al. also stressed regarding
assessment of functional ID and correlated it with symptoms
regardless of ejection fraction.13 These ﬁndings lay emphasis
on getting a complete iron proﬁle (including TSAT) in HF
patients, a practice still missing in the developing world,
including India.
In the 2012 ESC Guidelines for the diagnosis and treatment
of acute and chronic HF, the ESC recommended ID testing in HF
patients based on the assessments of ferritin and TSAT.10,11
This raises the question of which iron indices are the most
useful. Two are currently used: ferritin (a measure of stored
iron) and TSAT (a measure of circulating iron for functional
utilization). However, ferritin is also an acute-phase protein
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infection is present, but a low ferritin level is a clear
indication of ID (absolute). If ferritin is increased, TSAT
(<20%) can be used for the diagnosis of ID (functional). The
only limitation of TSAT is the circadian differences, since the
calculated value is dependent on the serum iron. Due to their
intrinsic limitations, the combination of thresholds of these
two parameters is suggested, as in FAIR-HF study (ferritin
<100 ng/mL or ferritin 100–300 ng/mL if TSAT <20%). The
ideal marker would probably be the soluble transferrin
receptor; however, this is not widely available or used in
clinical practice.4
Recommendations worldwide are being changed to incor-
porate the need to assess and treat ID in patients with chronic
HF.19 As our study indicates, ID is a common neglected burden
in Indian HF patients, and this requires the need for more
routine testing in future Indian guidelines.
In this study, we did not ﬁnd any signiﬁcant difference
regarding NYHA functional class among HF patients with
or without ID. Prior large-scale studies have established that ID
in HF patients correlates with NYHA functional class and work
capacity of patients.6,13 This difference may be attributed to
higher baseline NYHA class of our study patients with 69%
being in NYHA III/IV (mean 2.89  0.95). Being a single-center
study, the number of patients was also less compared to these
large-scale studies. Furthermore, this was an observational
study, so effect of iron supplementation on improvement of
NYHA class could not be analyzed. Various studies with
beneﬁcial effect of Iron supplementation in HF have been
published including two open, noncontrolled trials20–21 and
four randomized, placebo-controlled trials.8,22–24 Apart from
NYHA class and walking distance, Iron supplementation has
been shown to improve echocardiographic parameters of
myocardial performance.25,26 Unfortunately, such trials are
lacking in Indian patients. Our study tries to lay foundation
for future large-scale multicenter observational as well as
randomized interventional studies in Indian subjects.
4.1. Limitations of the study
This study is a single-center study conducted at a tertiary care
center in south Rajasthan. India being a vast country with
different cultures and food habits, it is difﬁcult to generalize
the ﬁndings necessitating multicenter larger studies. Second-
ly, the observational character of our study needs to be
acknowledged. The study was not designed to elucidate the
underlying detrimental mechanisms of ID in patients with HF.
No controls were taken to compare ID in subjects with or
without HF. Thirdly patients of both HFREF as well as HFPEF
were included without any separate analysis for these two.
5. Conclusion
Our study highlights the yet underestimated and neglected
burden of ID in HF patients in India. This study suggests
further large-scale studies to better characterize this easily
treatable condition and consider routine testing in future
Indian guidelines.Conﬂicts of interest
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